BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 24231356)

  • 1. Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration.
    Guo X; Disatnik MH; Monbureau M; Shamloo M; Mochly-Rosen D; Qi X
    J Clin Invest; 2013 Dec; 123(12):5371-88. PubMed ID: 24231356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S-nitrosylation of dynamin-related protein 1 mediates mutant huntingtin-induced mitochondrial fragmentation and neuronal injury in Huntington's disease.
    Haun F; Nakamura T; Shiu AD; Cho DH; Tsunemi T; Holland EA; La Spada AR; Lipton SA
    Antioxid Redox Signal; 2013 Oct; 19(11):1173-84. PubMed ID: 23641925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity.
    Qi X; Qvit N; Su YC; Mochly-Rosen D
    J Cell Sci; 2013 Feb; 126(Pt 3):789-802. PubMed ID: 23239023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drp1 phosphorylation by MAPK1 causes mitochondrial dysfunction in cell culture model of Huntington's disease.
    Roe AJ; Qi X
    Biochem Biophys Res Commun; 2018 Feb; 496(2):706-711. PubMed ID: 29397067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission.
    Reddy PH
    Drug Discov Today; 2014 Jul; 19(7):951-5. PubMed ID: 24681059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drp1/Fis1-mediated mitochondrial fragmentation leads to lysosomal dysfunction in cardiac models of Huntington's disease.
    Joshi AU; Ebert AE; Haileselassie B; Mochly-Rosen D
    J Mol Cell Cardiol; 2019 Feb; 127():125-133. PubMed ID: 30550751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation.
    Su YC; Qi X
    Hum Mol Genet; 2013 Nov; 22(22):4545-61. PubMed ID: 23813973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Drp1 hyperactivation reduces neuropathology and behavioral deficits in zQ175 knock-in mouse model of Huntington's disease.
    Zhao Y; Sun X; Qi X
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):319-323. PubMed ID: 30449600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease.
    Shirendeb UP; Calkins MJ; Manczak M; Anekonda V; Dufour B; McBride JL; Mao P; Reddy PH
    Hum Mol Genet; 2012 Jan; 21(2):406-20. PubMed ID: 21997870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hope for Huntington's disease? A novel approach for disease modification.
    Tunc S; Capetian P; Münchau A
    Mov Disord; 2014 Aug; 29(9):1117. PubMed ID: 24909788
    [No Abstract]   [Full Text] [Related]  

  • 11. VCP recruitment to mitochondria causes mitophagy impairment and neurodegeneration in models of Huntington's disease.
    Guo X; Sun X; Hu D; Wang YJ; Fujioka H; Vyas R; Chakrapani S; Joshi AU; Luo Y; Mochly-Rosen D; Qi X
    Nat Commun; 2016 Aug; 7():12646. PubMed ID: 27561680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity.
    Song W; Chen J; Petrilli A; Liot G; Klinglmayr E; Zhou Y; Poquiz P; Tjong J; Pouladi MA; Hayden MR; Masliah E; Ellisman M; Rouiller I; Schwarzenbacher R; Bossy B; Perkins G; Bossy-Wetzel E
    Nat Med; 2011 Mar; 17(3):377-82. PubMed ID: 21336284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Putative Drp1 Inhibitor mdivi-1 Is a Reversible Mitochondrial Complex I Inhibitor that Modulates Reactive Oxygen Species.
    Bordt EA; Clerc P; Roelofs BA; Saladino AJ; Tretter L; Adam-Vizi V; Cherok E; Khalil A; Yadava N; Ge SX; Francis TC; Kennedy NW; Picton LK; Kumar T; Uppuluri S; Miller AM; Itoh K; Karbowski M; Sesaki H; Hill RB; Polster BM
    Dev Cell; 2017 Mar; 40(6):583-594.e6. PubMed ID: 28350990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Drp1 mitochondrial translocation provides neural protection in dopaminergic system in a Parkinson's disease model induced by MPTP.
    Filichia E; Hoffer B; Qi X; Luo Y
    Sci Rep; 2016 Sep; 6():32656. PubMed ID: 27619562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli.
    Costa V; Giacomello M; Hudec R; Lopreiato R; Ermak G; Lim D; Malorni W; Davies KJ; Carafoli E; Scorrano L
    EMBO Mol Med; 2010 Dec; 2(12):490-503. PubMed ID: 21069748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-molecule suppression of calpastatin degradation reduces neuropathology in models of Huntington's disease.
    Hu D; Sun X; Magpusao A; Fedorov Y; Thompson M; Wang B; Lundberg K; Adams DJ; Qi X
    Nat Commun; 2021 Sep; 12(1):5305. PubMed ID: 34489447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATAD3A oligomerization causes neurodegeneration by coupling mitochondrial fragmentation and bioenergetics defects.
    Zhao Y; Sun X; Hu D; Prosdocimo DA; Hoppel C; Jain MK; Ramachandran R; Qi X
    Nat Commun; 2019 Mar; 10(1):1371. PubMed ID: 30914652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Declines in Drp1 and parkin expression underlie DNA damage-induced changes in mitochondrial length and neuronal death.
    Wang DB; Garden GA; Kinoshita C; Wyles C; Babazadeh N; Sopher B; Kinoshita Y; Morrison RS
    J Neurosci; 2013 Jan; 33(4):1357-65. PubMed ID: 23345212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis.
    Joshi AU; Saw NL; Vogel H; Cunnigham AD; Shamloo M; Mochly-Rosen D
    EMBO Mol Med; 2018 Mar; 10(3):. PubMed ID: 29335339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of CRMP2 in Regulation of Mitochondrial Morphology and Motility in Huntington's Disease.
    Brustovetsky T; Khanna R; Brustovetsky N
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.